Investigating RNA modifications and treatment response in multiple myeloma
Official title: RNA m6A modifications and treatment response in multiple myeloma
Funded at University of Chicago · NIH-11064787 · Data updated 2026-11-12
This study is looking at how a special change in RNA, called m6A, might influence how well patients with multiple myeloma respond to treatment, with the goal of finding better ways to personalize care for those who struggle with their therapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | April 2, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $188,244 |
| NIH project number | 5R21CA283588-02 |
| Project ID | NIH-11064787 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with multiple myeloma, particularly those who have experienced treatment resistance or relapse.
✕Less likely to help
Patients with multiple myeloma who are in complete remission or have not yet received treatment may not benefit from this research.
What this research studies
This research focuses on understanding how specific RNA modifications, particularly N6-methyladenosine (m6A), affect the treatment response in patients with multiple myeloma, a type of blood cancer. The study aims to develop new quantitative methods to analyze these RNA modifications at a high resolution, which could help identify why some patients experience poor outcomes despite receiving modern therapies. By examining the role of m6A in disease progression and treatment resistance, the research seeks to uncover new prognostic factors that could guide personalized treatment strategies for patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and better prognostic tools for patients with multiple myeloma.
How similar studies have gone: While the role of RNA modifications in cancer is an emerging field, this specific approach to studying m6A in multiple myeloma is relatively novel and has not been extensively tested.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Chiu, Brian C-H — University of Chicago
- Study coordinator: Chiu, Brian C-H
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.